Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
Generated Narrative: Evidence 236960
version: 69; Last updated: 2025-03-20 18:40:09+0000
Profile: ComparativeEvidence
RelatesTo
- type: part-of
- targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
url: https://fevir.net/resources/Evidence/236960
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236960, outcomeId/313958, picoId/85798, sectionId/73215
name: Nonfatal_myocardial_infarction_from_MAGICapp_313958
title: MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
| Code | Value[x] |
| Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ComparativeEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
assertion:
There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.
variableDefinition
description:
Adults with type 2 diabetes
variableRole: Population
variableDefinition
description:
GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
variableRole: Exposure
comparatorCategory: GLP-1 RA
variableDefinition
description:
Nonfatal myocardial infarction
variableRole: Outcome
observed: Nonfatal myocardial infarction
synthesisType: SYSTEMATIC_REVIEW
studyDesign: NOTSET
statistic
description:
Risk Difference -0.7% (CI95 -2.4% to 1.1%)
statisticType: Risk Difference
quantity: -0.007
SampleSizes
NumberOfStudies NumberOfParticipants 1 463 AttributeEstimates
Type Range CI95 -0.024-0.011
statistic
description:
OR 0.95 (CI95 0.84 to 1.08)
statisticType: Odds Ratio
quantity: 0.95
SampleSizes
NumberOfStudies NumberOfParticipants 1 463 AttributeEstimates
Type Range CI95 0.84-1.08
certainty
description:
Due to serious imprecision
type: Overall certainty
rating: Moderate certainty
Subcomponents
Type Rating Risk of Bias NOTSET Inconsistency NOTSET Indirectness NOTSET Imprecision NOTSET Publication Bias NOTSET
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot2. Generated 2025-03-28
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change